Interventional Radiology Market: Business Challenges, Emerging Technologies & Competitive Landscape

Global Interventional Radiology Market: Scope and Methodology

This report on the global interventional radiology market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global interventional radiology market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

Read Full Report: http://www.transparencymarketresearch.com/interventional-radiology-market.html

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global Interventional Radiology market.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market size estimations involved in-depth study of services and product features of different types of services. Additionally, market related factors such as increasing preference for technologically advanced services, product innovation, and increasing prevalence of cancer and other chronic diseases in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Interventional Radiology Market: Segmentation

Based on product type, the global interventional radiology market has been segmented into x-ray, computed tomography, magnetic resonance imaging, and ultrasound. The market has been further studied from the point of view of major application. Based on application, the market has been categorized into angiography, balloon angioplasty, embolization, biopsy, vertebroplasty-Kyphoplasty, RF ablation and others. On the basis of end user, the market has been segmented hospitals, catheterization labs, ambulatory surgical centers and others.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/interventional-radiology-market.html

Interventional Radiology Market: Geographical and Competitive Dynamics

Geographically, the global interventional radiology market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Japan, India, Saudi Arabia, UAE, Brazil, and Mexico.

The report also profiles major players in the Interventional Radiology market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Agfa-Gevaert N.V., Fujifilm Holdings Corporation, GE Healthcare, Hitachi Medical Corporation, Hologic, Inc., Medtronic plc., Philips Healthcare, Siemens Healthineers, Teleflex Incorporated, and Toshiba Medical Systems Corporation.

Global Surgical Procedures Volume Market: Gynecology Segment Surging at Robust Rate, finds TMR

The global surgical procedures volume market is dominated by a few players, although they are facing significant competition from local players in respective regional markets. The availability of advanced wound closure material presents a potential threat for the sutures and staples market. However, surgical handheld instruments face major roadblock only from internal substitutes (electrosurgical devices), having no impact on the overall surgical equipment market.

The global surgical procedures volume market was valued at US$1.3 bn in 2014. Expanding at a healthy CAGR of 5.6% during the forecast period of 2015 to 2023, the valuation is estimated to reach US$2.2 bn by the end of 2024.

Vast Population Base makes Asia Pacific Most Profitable Region

On the basis of procedure, the global surgical procedure volume market has been segmented into cardiovascular, orthopedic, neurosurgery, ophthalmic, gynecology, and other procedures, including urology and dental. The ophthalmic procedure segment held the maximum share in the global market in 2014, accounting for US$42.3 bn that year, primarily due to increasing number of ophthalmic surgeries across the globe and the introduction of advanced surgical technologies. However, the gynecology procedure segment is anticipated to grow at a high CAGR of 6.6% during the forecast period. The prominent factors attributed to this growth include a rise in the prevalence of gynecology diseases, changing lifestyle, and surgical up-gradation. The report finds that in 2014, the volume of surgical procedures was 135,986,269, which is anticipated to reach 222,157,438 by 2023.

Read Full Report: http://www.transparencymarketresearch.com/surgical-procedures-volumes-market.html

Geographically, the report studies the regional markets of North America, Europe, Asia Pacific, Latin America, and the Rest of the World. In 2014, Asia Pacific held the maximum market share, at 40.3%, and the region is expected to remain highly prominent during the forecast period. This demand from Asia Pacific is owing to factors such as massive patient base, increasing incidence of cardiovascular diseases, traumatic injuries, neurological disorders, and the introduction of advanced surgical technologies.

Prevalence of Cardiovascular Diseases Driving Demand

Rising geriatric population directly affects the growth and development of cardiac pacemaker products. This is primarily due to the fact that elderly people are highly susceptible to heart diseases such as sick sinus syndrome and atrioventricular blockage. According to the American Heart Association, cardiovascular disease is the leading cause of death globally. Currently, 17.3 million deaths occur per year. A rise in injuries, technological advancements, and rising incidences of cardiovascular, gynecological, neurological, and urological disorders are also seen as factors boosting market growth

Conversely, the rising cost of healthcare as well as complications and infections related to surgical procedures are the factors that may hinder the growth of the global surgical procedures volume market. The shift towards minimally-invasive surgeries is seen as an opportunity in the market.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1289

The author of the report states, “The future of surgery includes making smaller scars, and giving rise to fewer complications. The focus will be on key technologies such as single-incision laparoscopic surgery (SILS).” The author also identifies the development of robotic surgeries for market players to focus on, which is now widely used in operating rooms to perform highly complex and intricate surgeries, with less pain and recovery time.

The information presented in this review is based on a Transparency Market Research report, titled, “Surgical Procedures Volume Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015–2023.”

Biomedical Refrigerators and Freezers Market: Plasma Freezers to Bring New Opportunities in Market Growth, says TMR

The global biomedical refrigerators and freezers market is fragmented in nature and hence display deep competitive rivalry amongst the already established players. This is the main reason why companies in this market are putting in efforts in order to sustain in the market through constant innovation. The leading companies in the market are Eppendorf AG, Thermo Fisher Scientific, Inc., Helmer Scientific, and Panasonic Healthcare Co., Ltd. These companies are leading the market owing to the extensive product range being introduced by them, robust marketing strategies, and their increasing geographic presence, as per Transparency Market Research (TMR).

The global biomedical refrigerators and freezers market is predicted to touch US$4,003.003 mn in 2022. On the basis of type, the segment of plasma freezers is predicted to lead the market over the forecast horizon. The reason for the dominance of this segment includes the rising count of apheresis procedures and the increasing demand to store fresh frozen plasma. In addition, plasma exchange has come up as the most extensively employed apheresis procedures within the U.S. This will raise the adoption of plasma freezers in research laboratories, hospital settings, and blood banks, thus propelling the growth of the overall market. The global plasma freezers market is predicted to touch US$1,195.515 mn in 2022.

Read Full Report: http://www.transparencymarketresearch.com/biomedical-refrigerators-freezers-market.html

Flourishing Medical Tourism Industry to Bring Exponential Market Growth in Asia Pacific

On the basis of end user, the segment of blood banks led the market in the past owing to the rising availability of expensive freezers and refrigerators within blood banks. On the other hand, the segment of research laboratories is predicted to hold the most lucrative opportunity in the market in forthcoming years owing to growing development in life science research in the developing and developed regions. In addition, the increasing support by government for the production of personalized medicines within developed regions will also fuel the growth of this segment.

Geographically, the North America biomedical refrigerators and freezers market emerged as the top market due to the proliferation of R&D institutes, increasing adoption of cutting-edge technologies, and the advanced healthcare infrastructure of this region. On the other hand, the Asia Pacific biomedical refrigerators and freezers market is poised to rise at the swiftest 6.4% CAGR over the forecast period. This is owing to increasing research and development done by the developing economies and the growing industry for medical tourism in the region of Asia Pacific.

Increasing Demand for Organ Transplant and Biopharmaceuticals to Drive Market Growth

There is an increasing occurrence of organ failures globally. Hence, the global biomedical refrigerators and freezers market is predicted to rise due to the rising demand for organ transplant and biopharmaceuticals. In addition, the growing support provided by government on clinical trials and research activities will positively impact the growth of the biomedical refrigerators and freezers market. Furthermore, technological developments have introduced a paradigm shift from the utilization of conventional equipment to developed technology-based equipment offering efficient energy consumption. Thus, the introduction of numerous technological developments in biomedical refrigerators and freezers are expected to bode well for the growth of the market for biomedical refrigerators and freezers.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4666

On the other hand, this market is highly fragmented in nature and this may result in lower revenues and higher volumes, thus negatively impacting the development of the market. “The increasing usage of refurbished equipment and huge cost of biomedical refrigerators and freezers may also pull back their demand, thus restraining market growth,” says a TMR analyst.

Nonetheless, the growing focus on commercialization and branding of freezers will bring new growth opportunities in the market, states a TMR analyst.

This information is based on the findings of a report published by Transparency Market Research titled, “Biomedical Refrigerators and Freezers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Cardiovascular Monitoring and Diagnostic Devices Market Responds to Impressive Progress in Medicine and Healthcare

Being the leading cause of death and witnessing a high rise in prevalence, the class of ailments that come under the purview of cardiovascular diseases is witnessing increased focus from healthcare, research, and government bodies alike. A large number of companies are venturing into the market with an innovative range of products for diagnosing and treating a variety of cardiovascular diseases. Research and development activities are being granted increasingly more funds and governments bodies are implementing various health schemes aimed at reducing the prevalence and improving awareness about cardiovascular diseases.

Transparency Market Research states that the global cardiovascular monitoring and diagnostic devices market held an opportunity of US$1.8 bn in 2015. The market is expected to expand at a 6.4% CAGR over the period between 2016 and 2024, and rise to a valuation of US$3.1 bn by 2024.

Electrocardiogram (ECG) Systems Lead on Account of Cost Effectiveness and High Efficiency

The product segment of ECG systems presently holds the largest share in the global cardiovascular monitoring and diagnostic devices market. The widespread presence and high preference for ECG systems in developed and developing regions alike are key to the segment’s leading market position. ECG systems are expected to remain the key contributor to the market’s overall revenues over 206 and 2024 as well, expanding at a 6.3% CAGR in the global market.

Read Full Report: http://www.transparencymarketresearch.com/crdiovascular-monitoring-diagnostic-devices.html

However, the segment of implantable loop recorders is expected to witness the fastest expansion, a 7.1% CAGR from 2016 to 2024. The segment is projected to benefit from the rising awareness about the use of these devices in diagnosing syncope. As several cases of the disease remain undiagnosed when other conventional diagnostic methods are used, implantable loop recorders are gaining an increased level of adoption across medical diagnostic centers globally. The valuation of the segment is expected to reach US$152.7 mn by 2024.

The segment of Holter monitors also holds immense growth promise owing to the rising prevalence of conditions such as arrhythmia and conduction block. The segment was valued at US$416.1 mn in 2015 and is expected to expand at a high single-digit CAGR from 2016 to 2024.

North America to Continue Taking Largest Share of Pie but Emerging Economies Hold More Promise

North America accounted for the largest share of the overall revenues of the global cardiovascular monitoring and diagnostic devices market in 2015. The region is expected to remain the largest market over the period between 2016 and 2024 as well. Factors such as favorable reimbursement policies, high awareness about available diagnosis and treatment methods among patients and physicians, favorable reimbursement policies, and efficient healthcare infrastructure are factors that will help North America remain at the forefront of the global market. Europe, the second largest contributor to the global cardiovascular monitoring and diagnostic devices market in 2015, will also remain a lucrative owing to large scale healthcare infrastructure development activities and rising prevalence of cardiovascular disease.

View exclusive Global strategic Business Report :http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2385

However, developing regions such as Latin America and Asia Pacific will present the most promising growth opportunities for the global cardiovascular monitoring and diagnostic devices market over the period between 2016 and 2024. The presence of vast untapped growth prospects, rising healthcare expenditure, and increasing awareness about the efficiency of available techniques and devices in effectively curing several cardiovascular conditions will remain key to the overall growth of the market.

Several research studies also state that the risk of cardiovascular diseases is substantially high in mid- and low-income economies. This substantiates the fact that a large variety of cardiovascular monitoring and diagnostic devices will be consumed in Asia Pacific and Latin America in the next few years. The market for these devices will expand at a 7.5% in Asia Pacific and a 7.3% CAGR in Latin America over the period between 2016 and 2024.

In the highly dynamic global market for cardiovascular monitoring and diagnostic devices market, the top two vendors, GE Healthcare and Philips Healthcare accounted for a more than 55% of the global market in 2015. Other key vendors in the market are Spacelabs Healthcare, St. Jude Medical, Inc., and Siemens Healthcare.

New Trends of Synthetic Biology Market with Worldwide Industry Analysis to 2019

A new Transparency Market Research report states that the global synthetic biology market stood at US$1.8 bn in 2012 and is predicted to reach US$13.4 bn by 2019. It is predicted to expand at a whopping CAGR of 32.60% from 2013 to 2019. The title of the report is “Synthetic Biology Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019.” 

Synthetic biology is a synergistic combination of biology and engineering for the construction of artificial biological system in order to gain desired functions (i.e. to reduce cost or improve efficacy). It comprises nascent technologies that enable synthesis of novel biological parts and organisms that are used in the field of healthcare, chemicals, agriculture and others (biosecurity, R&D and energy and environment). The synthetic biology market is witnessing rapid growth owing to increase in demand for renewable fuels and bio-based chemicals and inexpensive drugs and vaccines that utilizes synthetic biology technologies and products. In addition, participation of various organizations such as BioBricks, DIYbio and SynBERC, for the development of synthetic biology field will further augment the growth of this market during the forecast period. However, high cost and strict regulations to use synthetic biology techniques hampers the growth of this market. The global synthetic biology market is estimated to be USD 1,769.8 million in 2012 and is expected to reach USD 13,375.5 million by 2019, growing at a CAGR of 32.6% from 2013 to 2019.

Read Full Press Release: http://www.transparencymarketresearch.com/pressrelease/synthetic-biology-market.htm

Synthetic biology market is segmented mainly by products, by technologies and by applications. Synthetic biology, by product segment is classified as core products and enabling products. Core products are further segmented into synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. The synthetic biology market by core products was dominated by synthetic DNA market in 2012 owing to the commercial availability of this product, compared to other synthetic core products expected to be launched in the market in coming years.

Synthetic biology market, by technologies is segmented as genome engineering, DNA sequencing, bioinformatics and biological components and integrated systems. Genome engineering technology can be used to modify genetic foods, gene cloning and gene therapy. Thus, application of genome engineering increases the scope to utilize this technique and hence accentuates the growth of this market.

Applications of synthetic biology are healthcare, chemicals, agriculture and others. Synthetic biology in healthcare holds largest market share in terms of revenue due to high utilization of synthetic biology techniques to produce cheap drugs and vaccines. Also, commercial availability of synthetic DNA and synthetic genes supports the growth of the healthcare application in the synthetic biology market. Agriculture segment is expected to grow at the highest growth rate during the forecast period.

Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=421

Europe contributed the largest share of the global synthetic biology market in 2012 and is expected to grow consistently, owing to increasing efforts of government and private organizations towards the development of this field. North America contributed the second largest share of the total market in 2012. Introduction of novel technologies by will help the growth of this market in North America. The Asia-Pacific region is expected to witness the fastest growth due to support of international organizations (e.g. Biotechnology Industry Organization and others) for the growth of synthetic biology in Asia-Pacific.

In terms of key players, the global synthetic biologymarket is highly fragmented with presence of a large number of players that includeBristol Mayer, Gevo, Inc., Life Technologies, DSM, DuPont, Inc., Genomatica, Inc., LS9, Inc.,Amyris, Inc. and others.

Synthetic Biology Market to Reach US$13.4 bn by 2019 due to Increasing Demand for Enhanced Vaccines and Drugs

Synthetic biology is a synergistic combination of biology and engineering for the construction of artificial biological system in order to gain desired functions (i.e. to reduce cost or improve efficacy). It comprises nascent technologies that enable synthesis of novel biological parts and organisms that are used in the field of healthcare, chemicals, agriculture and others (biosecurity, R&D and energy and environment). The synthetic biology market is witnessing rapid growth owing to increase in demand for renewable fuels and bio-based chemicals and inexpensive drugs and vaccines that utilizes synthetic biology technologies and products. In addition, participation of various organizations such as BioBricks, DIYbio and SynBERC, for the development of synthetic biology field will further augment the growth of this market during the forecast period. However, high cost and strict regulations to use synthetic biology techniques hampers the growth of this market. The global synthetic biology market is estimated to be USD 1,769.8 million in 2012 and is expected to reach USD 13,375.5 million by 2019, growing at a CAGR of 32.6% from 2013 to 2019.

Read Full Press Release: http://www.transparencymarketresearch.com/pressrelease/synthetic-biology-market.htm

Synthetic biology market is segmented mainly by products, by technologies and by applications. Synthetic biology, by product segment is classified as core products and enabling products. Core products are further segmented into synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. The synthetic biology market by core products was dominated by synthetic DNA market in 2012 owing to the commercial availability of this product, compared to other synthetic core products expected to be launched in the market in coming years.

Synthetic biology market, by technologies is segmented as genome engineering, DNA sequencing, bioinformatics and biological components and integrated systems. Genome engineering technology can be used to modify genetic foods, gene cloning and gene therapy. Thus, application of genome engineering increases the scope to utilize this technique and hence accentuates the growth of this market.

Applications of synthetic biology are healthcare, chemicals, agriculture and others. Synthetic biology in healthcare holds largest market share in terms of revenue due to high utilization of synthetic biology techniques to produce cheap drugs and vaccines. Also, commercial availability of synthetic DNA and synthetic genes supports the growth of the healthcare application in the synthetic biology market. Agriculture segment is expected to grow at the highest growth rate during the forecast period.

Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=421

Europe contributed the largest share of the global synthetic biology market in 2012 and is expected to grow consistently, owing to increasing efforts of government and private organizations towards the development of this field. North America contributed the second largest share of the total market in 2012. Introduction of novel technologies by will help the growth of this market in North America. The Asia-Pacific region is expected to witness the fastest growth due to support of international organizations (e.g. Biotechnology Industry Organization and others) for the growth of synthetic biology in Asia-Pacific.

In terms of key players, the global synthetic biologymarket is highly fragmented with presence of a large number of players that includeBristol Mayer, Gevo, Inc., Life Technologies, DSM, DuPont, Inc., Genomatica, Inc., LS9, Inc.,Amyris, Inc. and others.

Life Science Reagents Market to Reach US$25.7 bn by 2020 owing to Rising Activities of R&D within the Field of Pharmaceuticals

Life science reagents include reagents that are used in biotechnology, bioscience and pharmaceutical industries. Since the last decade, the global life science reagents market has experienced impressive growth due to factors such as technology advancement and expansion in applications of biotechnology and biosciences in the field of healthcare and pharmaceuticals. Some other factors contributing to the growth of the life science reagents market include increasing disease prevalence and rise in their mortality rates, aging of population and increased research and development activities in the field of biosciences, biotechnology and pharmaceuticals. Based on the commercially available life science reagent products, the global life science reagents market is categorized as PCR reagent kits, cell and tissue culture reagents, flow cytometry reagents, electrophoresis reagents, chromatography reagents, in-vitro diagnostic reagents and others. In addition, the global life science reagents market is segmented on the basis of end users, namely, commercial and contract manufacturers, research and academics, clinical laboratories, and forensic laboratories.

Read Full Press Release: http://www.transparencymarketresearch.com/pressrelease/life-sciences-reagents-analytical-reagents.htm

Chromatography reagents are the most widely used reagent products thus, capturing the highest market share in the overall life science reagents market. Wide use of chromatography in almost every aspect of biotechnology-related research and product development is the prime contributing factor for the dominance of this segment. On the other hand, the market share of electrophoresis reagents is the lowest as compared to other products available in the overall life science reagents market. Technological advancement and increasing initiatives towards the expansion of scope of biotechnology and life science has led to perpetual rise in demand for life science reagents worldwide.

In terms of end users, research and academic institutions are the largest consumers of life science reagents. Technological development and corresponding rise in the number of available skilled labor in emerging economies have widened the scope for research outsourcing in the developing markets of India and Brazil. Processes such as pharmaceutical contract manufacturing and cosmetic product manufacturing constitute the largest commercial consumers of life science reagents. Due to the requirement of high capital investment to perform stability studies, formulation development and phase-I trials, several pharmaceutical companies outsource drug development operations to contract manufacturing companies to focus on their core activities of manufacturing drugs and marketing, thereby controlling the in-house budget.

The global life science reagents market is fragmented in terms of presence of a large number of multinational and local players. The mature market players such as Sigma Aldrich, Abbott Laboratories, Life Technologies, Bio-Rad and others currently dominate this market with their patent protected products and intensive growth strategies of acquiring new market entrants providing breakthrough technologies. In addition, large patent repositories of the established market players restrains the entry and growth of new players in the life science reagents market.

Get a Free Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1162

Geographically, North America dominates the global life science reagents market and is followed by Europe. Asia-Pacific is expected to show the highest growth rate owing to factors such as increasing research and development activities, rise in the number of government aids, business clusters and trade conglomerates to strengthen biotechnology industry in the respective national markets and rise in the availability of skilled manpower at cheaper cost, thereby increasing the scope for outsourcing of biotech projects. New trend of outsourcing research activities in Asia-Pacific is one of the major driving forces for the growth of the life science reagents market in this region. Countries such as Brazil, Mexico and Argentina in the Rest of the World (RoW) region are adopting strategies such as formation of biotechnology clusters and attracting foreign investments to boost the domestic biotechnology industry. However, stringent regulatory rules restrain the entry of new products in the market and thus, restrict the growth of life science reagents market in these countries.

Global Regenerative Medicine Market to Reach US$6.5 bn by 2019, Propelled by Increasing Demand for Tissue Engineering and Stem Cell Therapy

Regenerative medicine, according to the US National Institutes of Health (NIH), is the process of developing functional tissues for the repair and/or replacement of damaged organs or tissues. Having lost function due to disease, congenital defects, and age, these tissues or organs are regenerated to establish and restore normal function.

Regenerative medicine is used in a wide range of applications including neurology, musculoskeletal, cardiovascular, and orthopedic. Earlier this month, a study showed that a new regenerative medicine appears to relieve eye pain, light sensitivity, and burning, and stimulate faster tissue repair following eye surgery. Findings by a team of researchers in Turkey suggest that this new compound can be beneficial for all those patients who undergo refractive surgery and corneal implants.

Read Full Report: http://www.transparencymarketresearch.com/regenerative-medicines-market.html

Demand for Tissue Engineering to Rise amid High Cost of Biomaterials

Regenerative medicine is an emerging branch of medical science and is being extensively used to treat cardiovascular disease, musculoskeletal disease, and orthopedic disorders. The growing prevalence of bone and joint disorders and the rise in orthopedic surgeries have fuelled the demand for regenerative medicines. Furthermore, technological innovations in stem cell therapy, biomaterials, and tissue engineering have supported the growth of the global regenerative medicines market. However, regulatory constraints pose a threat to the development of regenerative medicines. “Ethical issues related to allogeneic bone grafts and stem cell therapy, and post implantation infections are impeding the growth of the overall market,” the analyst states.

Technology has played a pivotal part in the success of regenerative medicines. Favorable reimbursement policies had augmented the demand for biomaterials in 2012. However, tissue engineering is being increasingly preferred over biomaterials. In fact, during the period between 2013 and 2019, tissue engineering is anticipated to expand at the fastest pace. “The high cost of biomaterials has led to their decreased adoption among patients,” the analyst mentions.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=419

The global regenerative medicine market is anticipated to expand at a CAGR of 12.8% during the period between 2013 and 2019. The overall market stood at a valuation of US$2.6 bn in 2012 and is projected to be worth US$6.5 bn by 2019.

Global Regenerative Medicine Market: Geographical Segmentation

Regionally, North America is the key contributor to the global regenerative medicine market due to the presence of several leading market players in the region, which has led to the latest advances in the field becoming easily available to patients. The well-funded R&D environment in the U.S. is also a key driver for the North America bone and joint regenerative medicine market, which is likely to remain a dominant regional market for regenerative medicine in the coming years.

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=419

Asia Pacific is likely to emerge as a leading regional market for bone and joint regenerative medicine in the coming years. The increasing patient pool of bone and joint conditions and the steady rise in healthcare expenditure in Asia Pacific are vital in ensuring sustained growth of the Asia Pacific regenerative medicine market in the coming years. Many key multinational players in the regenerative medicine market have identified Asia Pacific as a high-potential market for the future and have accordingly taken steps to expand their presence in the region.

Key players examined in the report include Smith & Nephew plc, Anika Therapeutics Inc., DePuy Synthes Inc., Baxter International Inc., Stryker Corporation, Medtronic Inc., Arthrex Inc., Zimmer Holdings Inc., and CONMED Corporation.

Growing incidence of cancer cases around the globe propels the Small Molecule Kinase Inhibitors Market

Small molecule kinase inhibitors are a form of enzyme inhibitors and are mostly used for the treatment of cancer. Protein kinase aids in the development and progression of tumors and small molecule kinase inhibitors help in obstructing unregulated cell cycle. The growing incidence of cancer cases around the globe is one of the major factors that propel the small molecule kinase inhibitors market. This has driven pharma companies and regulatory bodies to further speed up the process of clinical trials and drug approvals.

The research report analyzing the small molecule kinase inhibitors market studies the industrial landscape and presents a qualitative and quantitative portrait of the expected performance of the market from 2013 to 2019.

The data is derived from primary and secondary research, ensuring absolutely unbiased and authentic evaluation of the small molecule kinase inhibitors market. With the help of Porter’s five forces analysis, the report studies the role of buyers, suppliers, substitutes, new entrants, and competitors in the global market. Growth factors, challenges, and opportunities are identified and discussed at length and added emphasis is laid on government regulations that govern that pharmaceutical industry.

Overview of the small molecule kinase inhibitors market

The small molecule kinase inhibitors market is projected to witness robust growth in the coming years with rising popularity of the next generation of kinase inhibitor drugs, multi-targeted kinase inhibitors, and combination drug therapies. The use of kinase inhibitors for the treatment of various oncology and non-oncology diseases has grown, and while cancer end-use application areas are much stronger, non-cancer therapies are bound to gain interest.

Key kinase inhibitor drugs that have made a significant contribution to the global market include Sorafenib, Gefitinib, Iressa, Temsirolimus, Imatinib, Dasatinib, Rapamycin, Nilotinib, Everolimus, Sunitinib, Erlotinib, and Lapatinib. These commercially-available drugs are designed to target and treat specific diseases. There are numerous small molecule kinase inhibitor drugs in the pipeline, a factor that is anticipated to boost the global market. These pipeline drugs include Pazopanib, Cediranib, CP-690550, Bosutinib, Vandetanib, Alvocidib, Motesanib, and Ridaforolimus.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2110

Despite the availability of a number of kinase inhibitors, the anticipated rise in cancer cases all over the world poses high potential for the growth of the small molecule kinase inhibitors market. However, strict regulatory riders, lengthy approval procedures, and mounting costs of next-generation cancer drugs are matters of concern that hamper the expansion of the small molecule kinase inhibitors market.

Companies mentioned in the research report

Prominent names in the small molecule kinase inhibitors market include Bristol-Myers Squibb, Amgen, KAI Pharmaceuticals, Onyx Pharmaceuticals, Wyeth, OSI Pharmaceuticals, Glaxo SmithKline, Merck & Co, Pfizer, Bayer Schering Pharma, Roche, Sanofi-Aventis, AstraZeneca, Novartis, Genentech, and Celgene Corporation. The research study discusses these companies with respect to company overview, financial standing, product portfolio, recent developments in the small molecule kinase inhibitors market, mergers and acquisitions, business strategies, and SWOT analysis.

Non-Hodgkins Lymphoma (NHL) Therapeutics Market rises with rising prevalence of Non-Hodgkin’s lymphomas (NHL)

Lymphoma is one of the most hazardous and life threatening type of cancer, related to lymphocytes, an important type of white blood cells. Non-Hodgkin’s lymphomas (NHL) is a distinct group of blood cancer, which includes large variety of lymphomas, excluding Hodgkin’s lymphomas. Non-Hodgkin’s lymphoma (NHL) varies in their severity, from mild to fatal. According to a new classification of lymphomas published by WHO in 2008, the lymphomas are segmented into four different groups, instead of segregating as Hodgkin’s and Non-Hodgkin’s lymphomas. The list comprises of around 80 various types of lymphomas.

The major causes of Non-Hodgkin’s lymphomas (NHL) include chemical interaction, such as, interaction with diphenylhydantoin, polychlorinated biphenyls and other toxic compounds, autoimmune disorders, such as, rheumatoid arthritis, celiac sprue, Sjogren’s syndrome and others, medication and radiation therapy, infections, such as, H. pylori infection, HIV infection, hepatitis C viral infection, human T-cell leukemia virus, Epstein-Barr virus and others, genetic disorders such as ataxia telangiectasis syndrome, Klienfelter’s syndrome and others. Major symptoms of the disease includes night sweats, itchy skin, frequent high fever, breath shortness, loss of appetite and weight and painless sweating of lymph nodes present on various locations in the body.

The market of Non-Hodgkin’s lymphomas (NHL) is segmented on the basis of phase of the disease (severity), such as, phase I, II, III, and IV. Further, the market is segmented on the basis of types of Non-Hodgkin’s lymphomas (NHL), such as, AIDS-related lymphomas, Mantel Cell lymphoma, cutaneous T-cell lymphoma, blastic NK-cell lymphoma, T-cell leukemia, Burkitt’s lymphoma, follicular lymphoma, Waldenstrom’s Macroglobulinemia and many others. Furthermore, the market is segmented on the basis of therapeutic agents, such as, chemotherapy, stem cell therapy, radiations, novel targeted target therapy and other. A large number of therapeutic agents are used to treat Non-Hodgkin’s lymphomas (NHL), such as methotrexate, bortezomib, cyclophosphamide, bleomycin, chlorambucil, liposomal cytarabine, nelarabine, doxorubicin hydrochloride and many others.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2668

Moreover, the market is segmented on the basis of geography, such as, North America, Europe, Asia-Pacific and Rest of the World (RoW). At present, North America and Europe are the most prominent markets, owing to extensive research practices. However, Asia-Pacific and some countries in RoW region are expected to show lucrative growth in the upcoming period, owing to enhanced awareness about cancer and growing research practices.

The market of Non-Hodgkin’s lymphomas (NHL) is driven by many promoting forces, such as, rising prevalence of Non-Hodgkin’s lymphomas (NHL) and other types of cancer, extensive R&D practices, rising concern of the population towards effects of Non-Hodgkin’s lymphomas (NHL) and rise in medical and healthcare expenditure and infrastructure. Rising prevalence of Non-Hodgkin’s lymphomas (NHL) is one of the most important market drivers. According to American Cancer Society’s recent estimations, around 71,000 new patients are diagnosed with Non-Hodgkin’s lymphomas (NHL) in 2014, and the number of deaths is expected to be around 19,000 in 2014.

Request For Custom Research: http://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=2668

Furthermore, extensive R&D practices is another important market growth factor of this market. As of now, large number of pharmaceutical companies engaged in R&D practices in order to develop innovative formulations. For instance, Rituximab SC (Roche, Inc.) is under phase III studies. On the contrary, high cost of R&D and treatment and chronic side effects are the biggest hurdles in the market growth.

Some of the key players operating in Non-Hodgkin’s Lymphoma (NHL) Therapeutics market and engaged in the development of new formulations for Non-Hodgkin’s lymphomas (NHL) include F. Hoffmann LA Roche, Inc., Amgen, Inc. ,Eli Lilly and Company, Novartis International AG, Bayer AG, Pharmacyclics, Inc., Nordic Nanovector A/S, AbbVie, Inc. and many others.

Surgical Equipment Market - Worldwide Market Shares, Strategies, and Forecasts 2013 to 2019

According to a market research report published by Transparency Market Research, the global surgical equipment market is estimated to expand at a CAGR of 4.2% during the period between 2013 and 2019. The report, titled “Surgical Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” projects the global surgical equipment market to be worth US$11.28 bn by 2019. The overall market stood at a valuation of US$8.43 bn in 2013.

Surgical equipment are widely used during surgical procedures for making incisions, grasping certain tissue or skin, holding organs and tissue back, coagulation of blood vessels, providing access to site of operation, and closing the wound by stapling or stitching. Handheld instruments, staples, sutures, and electrosurgical devices are the most commonly used surgical equipment.

The report states that the year-on-year rise in the number of surgical procedures and the growing demand for minimally invasive procedures have fuelled demand from the global surgical equipment market. The rapidly increasing geriatric population and various technical advancements have also augmented the growth of the market.

However, the growing demand for advanced wound closure materials such as hemostats, glues, high-strength medical adhesives, fibrin, and other sealants will negatively impact the market’s growth during the forecast horizon. Additionally, the implementation of the Patient Protection and Affordable Care Act (PPACA) in the U.S. will hamper the growth of the market in North America. There have been a number of incidences of product recalls owing to the side effects associated with some surgical devices. This will also restrain the market. The overall market has a huge scope to grow across the emerging economies in Latin America, Asia Pacific, and Eastern Europe.

In terms of product type, the report broadly segments the global surgical equipment market into surgical sutures and staples, surgical handheld instruments, and electrosurgical devices. The surgical handheld instruments segment has been further divided into forceps, scalpels, retractors, and scissors. The demand for surgical sutures and staples was the highest in 2012 and the segment accounted for over 55% of the market. However, during the forecast period, the segment is expected to lose market share to electrosurgical devices.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=183

The report studies the surgical equipment market across four key regions: North America, Europe, Asia Pacific, and Rest of the World. Presently, the overall market is dominated by Europe and North America. However, growing public investment in the healthcare sector across Latin America and Asia Pacific is expected to fuel the demand for surgical equipment.

The report profiles some of the key players in the global surgical equipment market such as Covidien plc, Ethicon Inc., B. Braun Melsungen AG, Integra LifeSciences Holdings Corporation, CONMED Corporation, CareFusion Corporation, ERBE Elektromedizin GmbH, KLS Martin LP, Medicon eG, Aspen Surgical Products Inc., and Stryker Corporation. It also provides detailed information about the key players including their product portfolio, financial overview, business strategies, and recent developments.

Big Expectations for the future of Surgical Procedures Volume Market

Rising geriatric population across the world has been identified as a major factor fueling the growth of the surgical procedures market. This is primarily due to elderly people are highly susceptible to various chronic disorders. Moreover, growth in the global population over 65 years of age would highly affect market growth. According to the U.S. Census Board, people older than 65 years represented around 13% of the total population; this percentage is expected to reach 20% by 2030. According to the World Health Organization, the global geriatric population is anticipated to reach 1.5 billion by 2050. Countries aging at a rapid pace are the U.S., Japan, and Germany. Other factors driving the surgical procedures volume globally include increasing incidence of chronic disorders and rise in the number of trauma injury cases. The surgical procedures volume market has been segmented into cardiovascular, orthopedic, neurosurgery, ophthalmic, gynecology, and other procedures such as urology and dental.

The cardiovascular procedures segment has been further categorized into cardiac rhythm management devices implantations, interventional cardiology procedures, and heart transplantation. The interventional cardiology procedures sub-segment held the largest share of the cardiovascular procedures segment due to rising usage of cardiac catheterization in structural heart disease and is becoming complex due to increase in incidence of therapeutic catheterization. According to the American Heart Association, over 5 million people in the U.S. are diagnosed with heart valve disease each year, thereby making coronary angiography the leading segment in the interventional cardiology procedures market. The neurosurgery procedures segment has been sub-segmented into craniotomy, aneurysm coil embolization, CSF drainage, and CSF shunts. CSF drainage was the largest sub-segment of the neurosurgery segment, while the craniotomy sub-segment is anticipated to grow at the fastest rate during the forecast period due to recent developments in intraoperative imaging technologies. Orthopedic procedures have been categorized into three segments: joint replacement surgery, ligament/tendon repair surgery, and spine surgery. Joint replacement was the largest sub-segment of the orthopedic procedures segment. The sub-segment is further segmented into knee replacement, hip replacement, and shoulder replacement surgery. Knee replacement surgery dominated the joint replacement surgery segment as it is considered the most effective intervention for severe osteoarthritis, reducing pain and disability, and restoring patients to near normal function. The ophthalmic procedures segment has been categorized into three sub-segments: cataract surgery, refractive surgery, and glaucoma surgery. The cataract surgery sub-segment held the largest share of the global ophthalmic procedures market and in expected to expand at the highest CAGR due to technological advances and better efficacy of the procedures. Gynecology procedures have been categorized into three segments: hysterectomy surgery, uterine artery embolization, and cesarean section surgery. The continued growth of the global gynecology procedures market is attributed to changing lifestyle, increase in per capita income in the emerging markets, and rising prevalence of gynecological diseases such as menorrhagia, uterine fibroids, and cervical cancers globally. The other procedures segment includes urology procedures and dental procedures. The dental procedures sub-segment is anticipated to witness highest growth rate during the forecast period due to technical advancements leading to higher productivity and efficacy.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1289

Asia Pacific dominated the global surgical procedures market in 2014, accounting for a share of over 30% primarily due to large patient base, increasing incidence of cardiovascular diseases, traumatic injuries, neurological disorders, and introduction of advanced surgical technologies. Increase in the geriatric population also plays a major role in the growth of the surgical procedures market. Population over 65 years of age in Asia is likely to increase dramatically by 314%, from 207 million in 2000 to 857 million in 2050. This will increase the number of surgery procedures in the region. North America was the fastest growing market for surgical procedures in terms of volume during the forecast period from 2014 to 2023, due to growing innovation and adoption of new surgical technologies, high growth of minimally invasive surgeries, and C-section surgeries. Moreover, efficient reimbursement facilities, large health care infrastructure, rise in the health care expenditure, and high number of hospital beds per capita are anticipated to accelerate the medical infrastructure development in the U.S. making it the dominating segment in North America. Europe was the second largest market for surgical procedures in terms of volume in 2014, accounting for a share of 31.1% of the global market. Primary factors driving growth in the region include increase in the geriatric population and rise in the incidence of fall injuries, traffic-related injuries, cardiovascular diseases, and orthopedic cases. According to the European Commission database, the average number of surgical procedures for cardiac disorders has increased by around 20% from 2005 to 2010. Germany held the largest share of the surgical procedures market in Europe in 2014 due to the better reimbursement mechanism. Brazil accounted for the largest share of the surgery procedures market in Latin America. Growth of the market is attributed to high prevalence of chronic diseases, rise in geriatric population, and increase in health care expenditure. Mexico is expected to be the fastest growing market in Latin America due to low cost of medical treatments and high prevalence of chronic and infectious diseases.

Amylases Biofuel Enzymes Market - Latest Trends & Insights 2019

Besides the additional cost of fossil fuels, the global amylases biofuel enzymes market is projected to considerably gain from the increasing demand for energy derived from renewable resources. In a new study, titled “Amylases Biofuel Enzymes Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” Transparency Market Research (TMR) presents exhaustive details pertaining to various factors encouraging or inhibiting growth of market.

Overall, the market has been treading along a positive trajectory. However, the high level of carbon emissions from machines deployed at farm plants for biofuels creates bottlenecks for the market. Stringent regulations aimed at curbing carbon emission are therefore expected to hamper the amylases biofuel enzyme producers as well.

Various types of amylase biofuels are currently available in the market, among which cellulosic ethanol is becoming increasingly popular. In addition, scientists have discovered a new enzyme called Caffeoyl shikimate esterase, which is derived from plants. Such discoveries are touted as major breakthroughs in the production of cellulosic biofuels, which are mainly obtained from plastics, chemicals, and crop waste.

Caffeoyl shikimate esterase helps controlling the formation of lignin. Downregulating its functions could reduce 36% lignin per gram of stem materials, which will subsequently boost sugar levels up by four times. The development of this enzyme is therefore expected to prompt a revolution in the amylases biofuel enzymes market.

Regionally, amylases biofuel producers have been witnessing lucrative prospects in Brazil. The country presently leads the global amylases biofuel enzymes market and is expected to continue its dominance through the forecast period between 2013 and 2019. The U.S. has also emerged as an attractive market for amylases biofuel enzymes in the last few years. Ethanol is the most commonly used biofuel additive in the country.

Companies such as Danisco-Genencor and Novozymes have been engaged in the production of enzymes for several years. Together, they account for a dominant share in the production of enzymes. Besides this, Codexis has partnered with Shell to produce enzymes for second generation biofuels. In order to gain a competitive advantage, these companies have been focusing on product development.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2430

While the amylases biofuel enzymes market is still at a nascent stage, increasing investments in research and development by the aforementioned companies will fuel its growth in the forthcoming years. Furthermore, these companies are planning to invest in the development of myriad potential feedstock to scale up their production process. This is expected to drive the market during the forecast period.

Presently, the global amylases biofuel enzymes market is exhibiting a consolidated vendor landscape. Some of the prominent companies operating in the market include Enzyme Supplies Ltd., Enzyme Solutions Inc., aEnzyme Development Corporation, Jiangsu Boli Bioproducts Co. Ltd, Novozymes A/S, Montana Microbial Products, Schaumann Bioenergy, Noor Creations, Specialty Enzymes & Biotechnologies Co., Royal Dsm Nv, and Verenium Corporation

Big Expectations for the future of Opioid Induced Constipation Treatment Market

Transparency Market Research has published a new market report titled, “Opioid Induced Constipation Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023”. According to the report, the global opioid induced constipation treatment market was valued at US$0.4 bn in 2014 and is anticipated to expand at a CAGR of 31.2% from 2015 to 2023 to reach US$4.8 bn by 2023.

The report provides detailed analysis of current and emerging drugs for opioid induced constipation treatment, and the market is estimated based on type of drug class and dosage form of the drugs. Drug classes include mu-opioid receptor antagonist, chloride channel activator, and others based on their mechanism of action. Based on dosage form of drugs, the market has been segmented into solid, semi-solid, and liquid.

The chloride channel activator segment accounted for the largest share of the opioid induced constipation treatment market in 2014 due to first approval and launch of Amitiza in major countries. However, mu-opioid receptor antagonist was the fastest growing segment due to recent launch of the new drug Movantik and presence of pipeline drugs (naldemedine and other early stage drugs). Mu-opioid receptor antagonist drugs target the root cause of constipation by acting on specific peripheral opioid receptors, which revert the opioid action without affecting opioids analgesic action. Presently, Amitiza is the only available drug that belongs to the chloride channel activator class. However, mu-opioid receptor antagonist class consists of Movantik (AstraZeneca), Relistor (Valeant Pharmaceuticals, Inc.), and Naloxone. Additionally, naldemedine is in the late stage clinical trial. The drug is investigational, oral, mu-opioid receptor antagonist and is expected to launch in mid-2016. In August 2015, Shionogi’s naldemedine met primary and secondary endpoints in phase III clinical trial (COMPOSE II) to treat opioid induced constipation. Linaclotide is another potential drug, which is currently in phase II clinical trial. Phase I clinical trial (KODIAK16) is underway to assess the efficacy and safety of naloxegol in the treatment of opioid induced constipation in pediatric patients. The trial is expected to be completed in November 2017. Hence, launch of pipeline drugs during the forecast period is expected to boost the growth the PAMORA segment. The others segment includes Resolor (prucalopride), bulking agents (cellulose and psyllium), stool softeners (docusate), laxatives, and osmotic agents (lactulose, sorbitol, and polyethylene glycol). Major players in this segment are Boehringer Ingelheim GmbH and C.B. Fleet Company, Inc. Traditional laxatives are not legally approved for the treatment of opioid induced constipation. However, low cost of therapy, high awareness, and easy access to medicines accounted significant share of the opioid induced constipation treatment market. For instance, monthly cost of standard laxative therapy ranges from US$ 6 to US$ 80. However, monthly cost of Amitiza ranges from US$ 300 to US$ 400 and from US$ 600 to US$ 1000 for Relistor. Asia Pacific, Latin America, and Middle East & Africa are the major consumers of traditional medicines used to treat opioid induced constipation due to easy access, low cost, and less awareness about targeted therapy.

Furthermore, based on dosage form, the market has been segmented into solid, semi-solid, and liquid. The solid dosage form segment accounted for the largest share of the market in 2014. The segment is expected to maintain its leadership position during the forecast period. This is due to high patient compliance and launch of new drugs in solid form such as capsules, tablets, and pills. The semi-solid and liquid dosage form segments accounted for small shares of the market.

Get Free PDF Brochure for more Professional and Technical industry insights: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6862

The number of players operating in the opioid induced constipation treatment market is small, while demand for the therapy is high. Major players operating in the global opioid induced constipation treatment market are AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Bayer AG, C.B. Fleet Company, Inc., Boehringer Ingelheim GmbH, Daewoong Co. Ltd., and Cosmo Pharmaceuticals. Acquisitions and collaborations among major companies to commercialize OIC medicines are expected to boost the market during the forecast period. For instance, in March 2015, AstraZeneca and Daiichi Sankyo signed a co-commercialization agreement for Moventik in the U.S. In addition, in October 2014, Takeda and Sucampo entered into global license, development, and commercialization agreement for Amitiza. Hence, strategic agreements between companies are expected to drive the opioid induced constipation treatment market during the forecast period from 2015 to 2023.

Global Membrane Technology Market Boosted by Rise in Pharmaceutical Industry, Poised to Reach US$10.8 bn by 2019

The global membrane technology market is experiencing a significant rise in its valuation. The increasing research and development activities in membrane technology and the growth of several industries such as life sciences, pharmaceutical, and biopharmaceutical in terms of production volume are propelling this market substantially across the world. North America has been leading this market since the last few years. However, Asia Pacific is likely to emerge as the fastest growing membrane technology market across the world.

A research study by Transparency Market Research (TMR) has stated that the worldwide market for membrane technology stood at US$6.4 bn in 2013. Analysts estimate this market to expand at a CAGR of 9.10% between 2014 and 2019 and reach a value of US$10.8 bn by the end of 2019.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1848

What are the key factors driving the global membrane technology market?

The introduction of single-use disposable technology for biopharmaceutical products is the main driving force behind the robust growth of this market. Other than this, the implementation of stringent regulations regarding sterilizing drugs and medications during production is fueling the demand for membrane filtration, adding significantly to the market’s rise.

The continual advances introduced in the membrane technology are also boosting the market for membrane technology considerably across the world.

What are the major challenges faced by this market?

The global membrane technology market faces severe challenges from membrane fouling. In various processes such as membrane bioreactor, solutions or particles get deposited on the surface of the membrane, degrading its performance, thereby hindering the filtration process.

Apart from this, the high capital investment and operational cost associated with membrane technology also restrict companies to venture into this market, impeding its growth.

Browse Research Release:

http://www.transparencymarketresearch.com/pressrelease/global-membrane-technology-market.htm

What are the key strategies adopted by players operating in this for business expansion?

Most of the participants in the global membrane technology market are focusing on research and innovation as well as advancement of existing products to gain competitiveness in the market. One of the leading market players, the US-based GE Healthcare Life Sciences, has recently introduced a new ultrafiltration membrane technology for water treatment, named ZeeWeed 700B to be used in the offshore oil and gas market. This new horizontal-designed, inside-out UF membrane provides removal of solids in oil and gas applications and pre-treatment for seawater used for injection.

In May 2015, the company launched a novel nanofiltration membrane for seawater sulfate removal, specially designed for the upstream oil and gas market.

Mergers, acquisitions, and partnerships have also been popular among market players looking for strengthening their positions by expanding their product portfolios. Advantec MFS, Amazon Filters, Trisep Corp., Novasep, Koch Membrane System, Merck Millipore, 3M Co., and Sartorius are some of the other major enterprises operating in the worldwide membrane technology market.

Demand for Corporate Wellness Programs fueled by Concerns over Employee Wellness

Employers are implementing corporate wellness programs that focus on the improvement of the mental and physical health of their employees. These programs aid organizations in many ways in increasing productivity and reducing attrition rate. A market research report by Transparency Market Research, titled “Corporate Wellness Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,” focuses on the key trends pertaining to corporate wellness programs at organizational, regional, and global levels.

The report presents a comprehensive overview of the drivers and restraints and their impact on the global corporate wellness market. Government initiatives play a key role in the growth of this market. For instance, in the U.S., the Affordable Care Act with its reform has increased the cap on perks offered to employees for participating in health-related wellness. Also, several governments worldwide have mandated the implementation of wellness programs across medium and large organizations. Moreover, increasing industrialization has also played a vital role in the growth of the global corporate wellness market. The effectivity of these programs in retaining valuable human resource has increased its adoption in large as well as small organizations.

On the flip side, the success of corporate wellness programs depends on active participation of the employees. Currently, inefficient execution of these programs owing to low awareness and lack of participation are acting as key restraint in the growth of the global corporate wellness market. However, the rising adoption of reward-based approach has stirred up the active participation of employees. Moreover, improvements in wellness programs are likely to present notable opportunities to the service providers catering this market.

View exclusive Global strategic Business Report :http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4743

Geographically, the global corporate wellness market is segmented into North America, Asia Pacific, Latin America, Europe, and the Middle East and Africa. The inception of corporate wellness programs in North America and Europe happened many years ago and these are well rooted in these regions. However, Asia Pacific holds immense potential for service providers in the corporate wellness market. Rapid industrialization, increasing governments’ initiatives and improving economic conditions increase the scope for corporate wellness programs in this region.

The report provides insights into the competitive landscape of the global corporate wellness market. It also mentions profiles of the key players including their market share, revenue and cost structure, product specification, capacity, latest development, and contact information. It also offers a list of recommendations for the new market entrants. The key players in the global corporate wellness market are Corporate Wellness Solutions, FitLinxx, GCC Group, Provant Health Solutions, and Trotter Wellness. Also, Fitbit, an activity monitor manufacturer is expanding its business by offering corporate wellness solutions.

Disposable Pain Pumps Market Segment Forecast up to 2019

Pain pumps or intrathecal drug delivery is a method of delivering medication e.g. an opioid directly to the spinal cord. The system incorporates a small pump which is surgically placed under the abdominal skin that delivers medication through a catheter to the area around the spinal cord. Pain pumps are generally advised if all other traditional methods have failed to provide relief from long term symptoms. As the medication is delivered directly to the spinal cord, amount of dose required is much smaller than is needed with oral medication. The pumps are programmed to release small amount of medication over a period of time. These pumps can be programmed to deliver medication at a constant rate as well as in varying amount at different times of the day depending upon patient need and conditions. Once the pump reservoir gets over it can either be refilled with the help of a syringe or can be removed permanently.

Major drivers for disposable pain pump market includes significant pain reduction caused by Failed back surgery syndrome, Reflex sympathetic dystrophy, cancer pain. Ability to perform daily routine activities, low medication of dose, safety and effectiveness and ease of device removal also promotes the adoption for pain pump devices. Recent FDA approvals such as Prometra drug-delivery pump from Flowonix Medical Inc. and SynchroMed(R) II Programmable Pump from Medtronic, Inc. will help in driving demand for pain pumps in coming years. Surgical complications such as infections, side effects, spinal fluid leak leading to headache, occurrence of Inflammatory mass at the tip of the catheter breakdown of device due to failure of critical parts, component or battery are some of the restraining forces for this device market.

Request For PDF: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1825

Geographically North America and Europe market are leading because of trends in clinical practice, guidelines and protocols, reimbursement, regulatory affairs, and the competitive marketplace. Emerging economies of Asia, Middle East and Latin America are predicted to incur the high growth due to growing disease awareness and rising affordability in order to undertake such procedures.

Some of the key players contributing to the disposable pain pumps includes Advanced Infusion, Alaris Medical Systems Inc., Baxter International Inc., Deltec Inc. (Smiths Medical MD, Inc.),I-Flow Corp., McKinley Medical LLLP, Orthofix International, NVSgarlato Laboratories, Sorenson Medical Inc. Stryker Corp.